Skip to main content
Signal8
Launch Terminal

SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc.

NASDAQ:SABSHealthcare
+3.72%$3.35
AH$3.35+0.00%vs close
Mkt Cap$304.8M
Float77.74M
O/S90.99M
Vol
$ Vol
RVOL
Inst Own75.2%
SI6.2%
Earnings
Dilution
SAB Biotherapeutics, Inc. logoNASDAQ:SABS$3.35+3.72%
Phase Distribution
6 lead-sponsored trials·1 active·3 completed
Phase 14
Phase 22
(3 more as collaborator)
Status Overview
Recruiting1
Completed3
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Completed

    Study of SAB-176 in Healthy Adult Participants

    SAB-176

    Influenza A H1N1

    Enrollment
    62
    Start
    Jun 2021
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT04850898
  • Phase 2
    Recruiting

    SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

    High Dose SAB-142, Low Dose SAB-142

    Type 1 Diabetes

    Enrollment
    159
    Start
    Nov 2025
    Primary Completion
    Nov 2027est.
    Completion
    Dec 2028est.
    NCT07187531
  • Phase 1
    Completed

    Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

    SAB-185

    COVID-19, SARS-CoV2

    Enrollment
    28
    Start
    Jul 2020
    Primary Completion
    Dec 2020
    Completion
    Dec 2020
    NCT04468958
  • Phase 1
    Unknown status

    Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

    SAB-185

    COVID-19, SARS-CoV2

    Enrollment
    21
    Start
    Aug 2020
    Primary Completion
    Feb 2021
    Completion
    Nov 2021est.
    NCT04469179
  • Phase 1
    Completed

    Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

    SAB-176

    Influenza Type A, Influenza Type B +1

    Enrollment
    27
    Start
    Jul 2020
    Primary Completion
    Apr 2021
    Completion
    Apr 2021
    NCT04471038
  • Phase 1
    Unknown status

    A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

    Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo

    PHA1A

    Enrollment
    28
    Start
    Apr 2024
    Primary Completion
    Feb 2025est.
    Completion
    Feb 2025est.
    NCT06435936
Search ClinicalTrials.gov for “SAB Biotherapeutics”